Article

Tankyrase inhibition sensitizes cells to CDK4 blockade

2019-06-21

Abstract excerpt

Tankyrase (TNKS) 1/2 are positive regulators of WNT signaling by controlling the activity of the β-catenin destruction complex. TNKS inhibitors provide an opportunity to suppress hyperactive WNT signaling in tumors, however, they have shown limited anti-proliferative activity as a monotherapy in human cancer cell lines. Here we perform a kinome-focused CRISPR screen to identify potential effective drug combination...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5938bd9d-cc6d-571f-837c-e083db11d66f
DOI: 10.1101/677823

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Tankyrase inhibition sensitizes cells to CDK4 blockadeDOI 10.1101/677823Read

Tankyrase inhibition sensitizes cells to CDK4 blockade.Semantic proximity Read

Disruption of Wnt/β-Catenin Signaling and Telomeric Shortening Are Inextricable Consequences of Tankyrase Inhibition in Human CellsSemantic proximity Read

A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitorsSemantic proximity Read

Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling.Semantic proximity Read

A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.Semantic proximity Read

Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal CancerSemantic proximity Read

Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancerSemantic proximity Read

The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.Semantic proximity Read

Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer CellsSemantic proximity Read

A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cellsSemantic proximity Read

TTK Inhibitors as a Targeted Therapy for CTNNB1 (β-catenin) Mutant Cancers.Semantic proximity Read

Revving the Throttle on an Oncogene: CDK8 Takes the Driver SeatSemantic proximity Read